Are two of the most talked-about drugs in our culture today quietly reshaping how we understand the brain? Host Fiona Sanderson sits down with two researchers exploring the intersection of metabolic health and neuroscience - including how cannabis impacts the nervous system's ability to regulate blood flow to the brain, why GLP-1 drugs like Ozempic work brilliantly for some people and not at all for others, and what this could mean for the future of personalized medicine.

With cannabis now legal in Canada and GLP-1 agonists reshaping how we treat obesity and diabetes, these researchers are asking the questions patients - and the public - most need answered.

Featured guests:

Dr. Alexandre Caron, Associate Professor in the Faculty of Pharmacy at Laval University

Dr. Michael Tymko, Assistant Professor in the College of Biological Science, Department of Human Health Sciences at Guelph University

This work is supported by the Azrieli Foundation and the Heart and Stroke Foundation of Canada.

The Future Leaders in Canadian Brain Research Program is made possible thanks to an anchor gift from the Azrieli Foundation, and matched by Brain Canada through the Canada Brain Research Fund. It supports bold, early-career neuroscientists and helps bring their ideas to life.

Bold Minds is hosted by Fiona Sanderson. Our executive producers are Jillian Donnelly and Kate Shingler.

Our lead producer is Jess Schmidt, with editing by Morgane Chambrin.

Thank you for listening! If you enjoyed this episode, we’d appreciate it if you could send it to a friend. If you want to learn more about Brain Canada and the amazing research we support, please visit our website at

braincanada.ca.